NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
49 trialsNCT06638307 2026-04-13
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT07427394 2026-02-23
SERENA-1b
AstraZeneca
Phase 2 Not yet recruiting
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT07130383 2025-11-18
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2 Recruiting
NCT07173556 2025-09-15
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07101601 2025-08-03
Study of DM5167 in Patients With Advanced Solid Tumors
DIGMBIO
Phase 1 Recruiting
NCT06500494 2025-07-24
VINOREAL
Pierre Fabre Medicament
Recruiting
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06710990 2025-03-28
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Unknown
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT06354114 2024-04-09
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT05085002 2024-03-12
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT03474822 2024-02-20
Plasmodium Immunotherapy for Breast and Liver Cancers
CAS Lamvac Biotech Co., Ltd.
Phase 1/2 Recruiting
NCT03052634 2023-12-18
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
RemeGen Co., Ltd.
Phase 1/2 Completed
NCT06098599 2023-10-24
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Luye Pharma Group Ltd.
Phase 1 Completed
NCT06047184 2023-09-21
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
BeBetter Med Inc
Phase 1 Unknown
NCT04097756 2023-05-01
A Phase I Study of LX-039 Tablets
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Completed
NCT05775575 2023-03-20
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05753865 2023-03-03
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04436393 2022-06-22
GRECO-B
Guardant Health, Inc.
Completed
NCT05337657 2022-04-20
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Genor Biopharma Co., Ltd.
Phase 1 Unknown
NCT05274893 2022-03-11
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03538171 2021-07-09
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 3 Unknown
NCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT02952729 2021-02-24
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Mersana Therapeutics
Phase 1 Completed
NCT03125746 2021-01-05
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Unknown
NCT02054338 2019-08-28
VICTORIA
Pierre Fabre Medicament
Phase 3 Terminated
NCT03282825 2018-01-23
Clinical Study of Decitabine and Paclitaxel Combination Therapy
Dong Wha Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT02069093 2017-02-13
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Novartis
Phase 2 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00106145 2015-01-30
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01931943 2013-08-30
A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00562458 2013-02-05
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
AstraZeneca
Completed
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00328120 2010-11-17
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
AstraZeneca
Phase 1 Completed
NCT00915369 2010-02-08
A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer
Fresenius Kabi Oncology Ltd.
Phase 1 Unknown
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed
NCT00717951 2008-07-25
A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer
Academy Military Medical Science, China
Phase 2 Unknown